Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 172 results for "lacosamide"

Marksans gets USFDA approval and other top pharma news
India Infoline

New and Generic Drug Approvals: Vimpat

Drug Name(s) VIMPAT FDA Application No. (NDA) 022253 Active Ingredient(s) LACOSAMIDE Company UCB INC Original Approval or Tentative Approval Date October 28, 2008 Chemical Type 1New molecular entity (NME) Review Classification ... U.S. Food and Drug Administration, 1 month ago
PHARMA-ALEMBIC PHARMA-USFDA NOD United News of India, 1 month ago

9 images for lacosamide

Monthly Prescribing Reference, 5 days ago
Edu Bourse, 1 month ago
Monthly Prescribing Reference, 2 months ago
Money Control, 1 month ago
India Infoline, 1 month ago
Central Chronicle, 1 month ago
Money Control, 2 months ago, 2 months ago
India Infoline, 2 months ago
Edu Bourse

BRIEF-UCB announces new clinical trial data on lacosamide

May 30 UCB SA : * Says new clinical trial data, presented at the second Congress of the European Academy of Neurology, showed non-inferiority of lacosamide (VIMPAT) monotherapy compared with controlled-release carbamazepine among patients with ...
 Reuters UK1 month ago Positive VIMPATĀ® (lacosamide) monotherapy Phase III trial results presented at European Academy o...  Edu Bourse1 month ago Positive VIMPAT (lacosamide) monotherapy Phase III trial results presented at European Academy of Neurology Congress  FirstWord Pharma1 month ago

Breckenridge Pharmaceutical, Inc. Announces Final ANDA Approval for Lacosamide Tablets Vimpat

By a News Reporter-Staff News Editor at Drug Week Breckenridge Pharmaceutical, Inc. announced that Breckenridge and MSN Laboratories Private Limited were granted final approval for their ANDA lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg. a ...
 Pharmacy Choice1 month ago Breckenridge Pharmaceutical Announces Final ANDA Approval for Lacosamide Tablets (Vimpat)  FirstWord Pharma1 month ago
Monthly Prescribing Reference

Study Examines QoL/Mood Outcomes of Adjunct Seizure Therapy, Lacosamide

A 28-week open-label study of the adjunct antiepileptic drug, lacosamide, showed that it had a low risk of adverse mood effects and a low risk for overall effect on cognition. Similar to prior studies, this study also found a significant reduction ...
 Monthly Prescribing Reference5 days ago

Patent Issued for Process for the Preparation of Lacosamide and Its Novel Intermediate (USPTO 9346744)

By a News Reporter-Staff News Editor at -- Rao; Davuluri Ramamohan (Hyderabad, IN) has been issued patent number 9346744, according to news reporting originating out of Alexandria, Virginia, by VerticalNews editors. The patent's inventors are ...
 Equities.com3 weeks ago

New and Generic Drug Approvals: Lacosamide

Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to
 U.S. Food and Drug Administration1 month ago
Monthly Prescribing Reference

Long-Term Lacosamide Given Alone Thwarts Partial-Onset Seizures: Presented at AAN

You currently are not registered for any FirstWord Pharma services. Register to FirstWord Pharma for free access to 10 articles every 30 days: You can also: Wait 16 days for your content allowance to be renewed. Sign up for a free trial to ...
 FirstWord Pharma2 months ago Lacosamide Monotherapy Up to 800mg Safe for Partial-Onset Seizures  Monthly Prescribing Reference2 months ago

World Generic Markets Issue - IGBA Special 301 Submission Highlights Need For Common Ground - Research and Markets

Research and Markets has announced the addition of the "World Generic Markets Issue 281 (V15 I14)" report to their offering. From a pharmaceutical perspective, the USTR's Special 301 Report has generally been seen as an opportunity to criticise ...
 4 Traders1 week ago Enhancing Portfolios Crucial To Counter Slowing CNS Development - Research and Markets  4 Traders1 week ago

Brivaracetam in epilepsy: Added benefit not proven

By a News Reporter-Staff News Editor at Health & Medicine Week Brivaracetam (trade name: Briviact) has been approved since January 2016 as add-on therapy for adolescents from the age of 16 years and adults with epileptic seizures. The German ...
 Pharmacy Choice1 week ago Brivaracetam drug shows no added benefit for epilepsy  News-Medical.Net1 month ago

Sanofi gets Japan nod for alirocumab

Japan's Ministry of Health, Labour and Welfare (MHLW) has recommended approval for Regeneron ($REGN) and Sanofi's ($SNY) alirocumab (Praluent), a spokesman for the ministry said, setting up competition in the PCSK9 inhibitor space with the Amgen ...
 FiercePharma3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - lacosamide
Get updated on latest news & your favorite topics right in your inbox!
More     Less